2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1834 Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final Results from the phase 2 PRIMO trial: Outcomes in patients who proceeded to stem cell transplant

Jonathan Brammer, MD, Neha Mehta-Shah, MD, MSCI2, Barbara Pro, MD3, Jasmine Zain, M.D.4, Ohad S Bentur, MD5, David Sidransky, MD6, Pier Luigi Zinzani, MD, PhD7, Steven Horwitz, M.D.8
1 Ohio State University, Columbus, Ohio, United States
2 Washington University School of Medicine, Saint Louis, Missouri, United States
3 Columbia University, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, NY, United States
5 Secura Bio, Inc., Berkeley Heights, New Jersey, United States
6 Johns Hopkins University, Baltimore, Maryland, United States
7 University of Bologna, Bologna, Italy
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Introduction

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of aggressive malignancies associated with poor outcomes in the relapsed or refractory (R/R) setting, where median overall survival (mOS) is typically <6 months. Although allogeneic stem cell transplantation (allo-SCT) remains a potentially curative option for selected patients (pts), successful transplantation requires achievement of disease control and stable clinical status. Current single-agent therapies for R/R PTCL generally yield overall response rates (ORR) <30% (except brentuximab vedotin in anaplastic large cell lymphoma), limiting the number of pts eligible for SCT.

Duvelisib (DUV) is an oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ/γ and is approved in the US for the treatment of R/R chronic lymphocytic leukemia/small lymphocytic lymphoma after ≥2 prior systemic therapies. Its use in PTCL is investigational. In the phase 2, single-arm PRIMO trial (NCT03372057; Secura Bio, Inc), DUV demonstrated clinically meaningful activity in R/R PTCL. Here, we characterize outcomes among pts who achieved sufficient disease control with DUV to subsequently undergo SCT.

Methods

Eligibility criteria included adults with pathologically confirmed R/R PTCL and ≥1 prior regimen. After dose optimization, the optimal dose for the PRIMO expansion phase (PRIMO-EP) was DUV 75 mg BID for 2 cycles to maximize disease control, followed by 25 mg BID to mitigate late toxicities; continued until progressive disease or unacceptable toxicity. The primary endpoint was ORR by Independent Review Committee assessment (Lugano 2014). Pts could proceed to SCT at any time per investigator discretion (progression free survival [PFS] censored at SCT). Here we report outcomes of the pts who proceeded to SCT after PRIMO-EP, focusing on those proceeding to allo-SCT directly after DUV treatment.

Results

In the PRIMO-EP (N=123), pts had a median (range) age of 65 (21-92) yrs and median (range) of 2 (1-9) prior lines of therapy. Most common baseline histologies: PTCL-NOS (n=53), AITL (n=37), and ALCL (n=20). Efficacy outcomes: ORR 48%, complete response rate (CRR) 33%, median PFS 3.4 mos, median duration of response 7.9 mos, mOS 12.4 mos.

In total, 19 pts (15%) proceeded to SCT after PRIMO (15 allogeneic [2 haploidentical], 2 autologous, and 2 not specified). For all 19 SCT pts, outcomes with DUV were ORR: 74%, CRR: 63%, mPFS: 9.0 mo (95% CI 3.9, NR). Of the 15 allo-SCT pts, 2 received an intervening treatment between DUV and SCT. Analyses detailed in this abstract will focus on the 13 pts who proceeded to allo-SCT directly after DUV treatment. Baseline characteristics in these 13 pts were age 55 (21-69) yrs, 2 (15%) ≥65 years, median (range) prior lines: 2 (1-5), location: 11 US, 2 EU. Six (46%) had a prior auto-SCT. Pt histology was PTCL-NOS (n=7), AITL/TFH (n=5) , other (n=1). The median (range) time from last dose of DUV to SCT was 28 days (8, 137). For these 13 pts, median DUV treatment duration was 98 days (range 35, 275), and outcomes prior to SCT were ORR: 85%, CRR: 69%, PFS: 9.0 (3.9, NR). ORR was 85% (11/13) and CR 69% (9/13). mOS was not reached after median follow up of 35 mos, and 4-year survival probability was 75%. Data on relapse vs non-relapse mortality (NRM) was not available. The adverse event profile of DUV in pts who proceeded to SCT was consistent with that of the full intent-to-treat (ITT) population.

Conclusions

Allo-SCT remains one of the few potentially curative treatment options for pts with R/R PTCL. In PRIMO, the 13 pts who proceeded directly from DUV to allo-SCT achieved higher response rates and deeper responses to DUV versus the overall study population. These pts were younger, but their adverse event profile was generally consistent with that observed in the ITT population.

 

A limitation of this analysis is that SCT data were collected during routine post-study follow-up rather than through a dedicated transplant protocol; therefore, certain variables, including incidence of NRM, were unavailable. These data are being prospectively collected in the ongoing phase 3 TERZO study (DUV vs investigator’s choice of gemcitabine or bendamustine in R/R nodal TFH lymphoma).

 

Importantly, 15% of pts enrolled in PRIMO-EP were successfully bridged to allo-SCT following treatment with DUV monotherapy. These findings demonstrate that potentially curative SCT is feasible after disease control with DUV and contributes to durable clinical benefit in selected pts.

Neha Mehta-Shah, MD, MSCI: MDEducation - Honoraria; MedLive - Honoraria; Curio Science - Honoraria; BioAscend - Honoraria; C4 Pharmaceuticals - Research Funding; Seagen/Pfizer - Research Funding; Ono Pharmaceuticals - Research Funding; Daiichi Sankyo - Research Funding; Treeline Pharmaceuticals - Research Funding; AstraZeneca - Research Funding; Morphosys/Novartis - Research Funding; Novartis - Research Funding; Innate Pharmaceuticals - Research Funding; BMS/Celgene - Research Funding; Corvus Pharmaceuticals - Research Funding; Genenetch - Research Funding; Pfizer - Research Funding; SecuraBio - Research Funding; Autolous - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); SecuraBio - Consultancy (Includes expert testimony); Ono Pharmaceuticals - Consultancy (Includes expert testimony); Acrotech - Consultancy (Includes expert testimony)